Prognostic value of regadenoson myocardial single-photon emission computed tomography in patients with different degrees of renal dysfunction

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 8, 2014, Pages 933-940

  Bhatti, Sabha ^a,b   Hakeem, Abdul ^a   Dhanalakota, Sunitha ^b   Palani, Gurunanthan ^c   Husain, Zehra ^d   Jacobsen, Gordon ^b   Ananthasubramaniam, Karthik ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Department of Internal Medicine   (United States)

^d ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

Author keywords

Cardiac death; Chronic kidney disease; Prognosis; Regadenoson; Single photon emission computed tomography; Transient ischaemic dilation

Indexed keywords

REGADENOSON; TETROFOSMIN TC 99M; ADENOSINE A2 RECEPTOR AGONIST; BIOLOGICAL MARKER; ORGANOPHOSPHORUS COMPOUND; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART DISEASE; HUMAN; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURVIVAL; BIOASSAY; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DIAGNOSTIC USE; ELECTROCARDIOGRAPHY; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR; SCINTISCANNING; SURVIVAL RATE;

ADENOSINE A2 RECEPTOR AGONISTS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; PURINES; PYRAZOLES; RADIOPHARMACEUTICALS; RISK FACTORS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84904428817     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jeu036     Document Type: Article

References (21)

1. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Stressmyocardial perfusion single-photon emission computed tomography is clinically effective and cost effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. J Am Coll Cardiol 2004; 43:200-8. (Pubitemid 38201145)
2. Hachamovitch R, BermanDS, KiatH, Cohen I, Cabico JA, Friedman J et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996;93: 905-14. (Pubitemid 26074827)
3. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-43. (Pubitemid 28090682)
4. Valeti US, Miller TD, Hodge DO, Gibbons RJ. Exercise single-photon emission computed tomography provides effective risk stratification of elderly men and elderly women. Circulation 2005;111:1771-6. (Pubitemid 40525141)
5. Shaw LJ, Hendel RC, CerquieraM, Mieres JH, Alazraki N, Krawczynska E et al. Ethnic differences in the prognostic value of stress technetium-99m tetrofosmin gated single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;45:1494-504. (Pubitemid 40615625)
6. Hakeem A, Bhatti S, Dillie KS, Cook JR, Samad Z, Roth-Cline MD et al. Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation 2008;118:2540-9.
7. Garnock-Jones KP, CurranMP. Regadenoson. Am J Cardiovasc Drugs 2010;10:65-71.
8. Palani G, Husain Z, SalinasRC, KarthikeyanV, KarthikeyanAS, AnanthasubramaniamK. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol 2011;18:605-11.
9. Ananthasubramaniam K, Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S.Arandomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19: 319-29.
10. Aljaroudi W, Hermann D, Hage F, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage renal disease. Am J Cardiol 2010;105:133-5.
11. Myocardial Perfusion Imaging Market Guide (U.S.) Supplement to the U.S. Imaging Market Guide. Malvern, PA: Arlington Medical Resources, Inc; 2011.
12. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
13. Coceani M, Gimelli A, Carpeggiani C, L'Abbate A, Marzullo P. Clinical utility of estimated glomerular filtration rate in patients undergoing gated SPECT. J Nucl Cardiol 2009;16:384-90.
14. Al-Mallah MH, Hachamovitch R, Dorbala S, Di Carli MF. Incremental prognostic value of myocardial perfusion imaging in patients referred to stress single-photon emission computed tomography with renal dysfunction. Circ Cardiovasc Imaging 2009;2:429-36.
15. Hatta T, Nishimura S, Nishimura T. Prognostic risk stratification of myocardial ischaemia evaluated by gated myocardial perfusion SPECT in patients with chronic kidney disease. Eur J Nucl Med Mol Imaging 2009;36:1835-41.
16. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
17. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from theADVANCEMPI 2 trial. J AmColl Cardiol Img 2009; 2:959-68.
18. Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J et al. Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. J Am Coll Cardiol Img 2012;5: 1014-21.
19. Paoletti E, Cannella G. Left ventricular hypertrophy in chronic kidney disease. G Ital Nefrol 2006;23:560-8.
20. Bhatti S, Hakeem A, Dillie KS, Cook JR, Chang SM. Prevalence, prognosis, and therapeutic implications of unrecognized left ventricular systolic dysfunction in patients with anemia and chronic kidney disease. Congest Heart Fail 2010;16:271-7.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The seventh report of the JointNationalCommittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. (Pubitemid 37430158)